http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.
-
XenoTherapeutics to acquire Repare Therapeutics for $1.82 per share
-
Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.
-
Repare Therapeutics to present PLK4 inhibitor data at cancer conference
-
Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-
Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
-
Repare Therapeutics licenses cancer drug lunresertib to Debiopharm
-
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib
-
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results
-
Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics
-
Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025
-
Repare Therapeutics (RPTX) Announces Leadership Transitions
-
Repare Therapeutics Announces Leadership Transitions
-
Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Repare Therapeutics Inc. (RPTX) Provides Business and Clinical Update
-
Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results
-
Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions
-
Repare Therapeutics (RPTX) Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
-
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
-
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial
-
Repare Therapeutics Inc. (RPTX) Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
-
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
-
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
-
Repare Therapeutics Inc. (RPTX) Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
-
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
-
Repare Therapeutics Inc. (RPTX) Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
-
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
-
Repare Therapeutics (RPTX) Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment
-
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
-
Repare Therapeutics (RPTX) Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
-
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
-
Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024
-
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
-
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
-
Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results
-
Repare Therapeutics Inc. (RPTX) Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial
-
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
-
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
-
Repare Therapeutics (RPTX) Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
-
Repare Therapeutics (RPTX) Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
-
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
-
Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
-
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
-
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
-
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
-
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
-
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
-
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664
-
Repare Therapeutics Inc. (RPTX) to Regain Global Rights to Camonsertib
